THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS

Objective: The programmed cell death 1 (PD-1) receptor is an immune checkpoint receptor expressed by activated T cells. PD-1 inhibits the immune system by binding to its ligands expressed on tumor cells. Nivolumab and pembrolizumab are some of the monoclonal antibodies that inhibit the PD-1. We pres...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Veysel GOK, Firdevs AYDIN, Alper OZCAN, Ebru YILMAZ, Ekrem UNAL, Musa KARAKUKCU, Türkan PATIROGLU, Mehmet Akif OZDEMIR, Filiz KARAMAN, Orhan GORUKMEZ, Ozlem GORUKMEZ, Atil BISGIN
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/8fc9fac9b6054cc2b9b1c3e60f6e9bd4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8fc9fac9b6054cc2b9b1c3e60f6e9bd4
record_format	dspace
spelling	oai:doaj.org-article:8fc9fac9b6054cc2b9b1c3e60f6e9bd42021-11-10T04:39:17ZTHE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS2531-137910.1016/j.htct.2021.10.1098https://doaj.org/article/8fc9fac9b6054cc2b9b1c3e60f6e9bd42021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921012451https://doaj.org/toc/2531-1379Objective: The programmed cell death 1 (PD-1) receptor is an immune checkpoint receptor expressed by activated T cells. PD-1 inhibits the immune system by binding to its ligands expressed on tumor cells. Nivolumab and pembrolizumab are some of the monoclonal antibodies that inhibit the PD-1. We present our experience with eight cases which were treated with nivolumab for different malignant diseases in our clinic. Methodology: A total of eight patients (5 girls, 3 boys) aged between 4 and 16 years were treated with nivolumab at 3mg/kg/dose approximately twice a week in Erciyes University Pediatric Hematology clinic between 2019-2021. Nivolumab treatments of seven patients were given median 11 (4-32) doses and discontinued due to progression at a median 6 months (2-17 months). Results: Four patients were diagnosed with miss match repair syndrome in addition to their malignant disease. Non-Hodgkin lymphoma (two with T-cell and one with histiocyte-rich B-cell) in three patients, brain tumor (pons glioma, midline glioma, glioblastoma multiforme) in three patients, germ cell tumor (yolk salk, immature teratoma) in two patients, one patient had colon adenocarcinoma in addition to brain tumor. Except for nausea in a patient, no drug-related side effect was observed in patients. Conclusion: Nivolumab was well tolerated in patients with CMMRD syndrome with some transient partial responses. There is a risk of developing secondary cancer in patients with CMMRD syndrome. Further studies are needed due to the limited use in children.Veysel GOKFirdevs AYDINAlper OZCANEbru YILMAZEkrem UNALMusa KARAKUKCUTürkan PATIROGLUMehmet Akif OZDEMIRFiliz KARAMANOrhan GORUKMEZOzlem GORUKMEZAtil BISGINElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S65- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Veysel GOK Firdevs AYDIN Alper OZCAN Ebru YILMAZ Ekrem UNAL Musa KARAKUKCU Türkan PATIROGLU Mehmet Akif OZDEMIR Filiz KARAMAN Orhan GORUKMEZ Ozlem GORUKMEZ Atil BISGIN THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
description	Objective: The programmed cell death 1 (PD-1) receptor is an immune checkpoint receptor expressed by activated T cells. PD-1 inhibits the immune system by binding to its ligands expressed on tumor cells. Nivolumab and pembrolizumab are some of the monoclonal antibodies that inhibit the PD-1. We present our experience with eight cases which were treated with nivolumab for different malignant diseases in our clinic. Methodology: A total of eight patients (5 girls, 3 boys) aged between 4 and 16 years were treated with nivolumab at 3mg/kg/dose approximately twice a week in Erciyes University Pediatric Hematology clinic between 2019-2021. Nivolumab treatments of seven patients were given median 11 (4-32) doses and discontinued due to progression at a median 6 months (2-17 months). Results: Four patients were diagnosed with miss match repair syndrome in addition to their malignant disease. Non-Hodgkin lymphoma (two with T-cell and one with histiocyte-rich B-cell) in three patients, brain tumor (pons glioma, midline glioma, glioblastoma multiforme) in three patients, germ cell tumor (yolk salk, immature teratoma) in two patients, one patient had colon adenocarcinoma in addition to brain tumor. Except for nausea in a patient, no drug-related side effect was observed in patients. Conclusion: Nivolumab was well tolerated in patients with CMMRD syndrome with some transient partial responses. There is a risk of developing secondary cancer in patients with CMMRD syndrome. Further studies are needed due to the limited use in children.
format	article
author	Veysel GOK Firdevs AYDIN Alper OZCAN Ebru YILMAZ Ekrem UNAL Musa KARAKUKCU Türkan PATIROGLU Mehmet Akif OZDEMIR Filiz KARAMAN Orhan GORUKMEZ Ozlem GORUKMEZ Atil BISGIN
author_facet	Veysel GOK Firdevs AYDIN Alper OZCAN Ebru YILMAZ Ekrem UNAL Musa KARAKUKCU Türkan PATIROGLU Mehmet Akif OZDEMIR Filiz KARAMAN Orhan GORUKMEZ Ozlem GORUKMEZ Atil BISGIN
author_sort	Veysel GOK
title	THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
title_short	THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
title_full	THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
title_fullStr	THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
title_full_unstemmed	THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
title_sort	effect of nivolumab in pediatric malignant tumors: a single center experience with eight patients
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/8fc9fac9b6054cc2b9b1c3e60f6e9bd4
work_keys_str_mv	AT veyselgok theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT firdevsaydin theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT alperozcan theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT ebruyilmaz theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT ekremunal theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT musakarakukcu theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT turkanpatiroglu theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT mehmetakifozdemir theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT filizkaraman theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT orhangorukmez theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT ozlemgorukmez theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT atilbisgin theeffectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT veyselgok effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT firdevsaydin effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT alperozcan effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT ebruyilmaz effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT ekremunal effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT musakarakukcu effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT turkanpatiroglu effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT mehmetakifozdemir effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT filizkaraman effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT orhangorukmez effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT ozlemgorukmez effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients AT atilbisgin effectofnivolumabinpediatricmalignanttumorsasinglecenterexperiencewitheightpatients
_version_	1718440576838270976

THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS

Ejemplares similares